Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
0.7990
-0.0063 (-0.78%)
Jun 26, 2025, 4:00 PM - Market closed

Sutro Biopharma Statistics

Total Valuation

Sutro Biopharma has a market cap or net worth of $67.48 million. The enterprise value is -$160.09 million.

Market Cap 67.48M
Enterprise Value -160.09M

Important Dates

The next estimated earnings date is Tuesday, August 12, 2025, after market close.

Earnings Date Aug 12, 2025
Ex-Dividend Date n/a

Share Statistics

Sutro Biopharma has 84.46 million shares outstanding. The number of shares has increased by 35.16% in one year.

Current Share Class 84.46M
Shares Outstanding 84.46M
Shares Change (YoY) +35.16%
Shares Change (QoQ) +0.72%
Owned by Insiders (%) 1.56%
Owned by Institutions (%) 53.50%
Float 65.81M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 0.99
Forward PS 1.15
PB Ratio n/a
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 2.16

Current Ratio 2.16
Quick Ratio 1.97
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -6.82

Financial Efficiency

Return on equity (ROE) is -679.15% and return on invested capital (ROIC) is -235.59%.

Return on Equity (ROE) -679.15%
Return on Assets (ROA) -39.55%
Return on Invested Capital (ROIC) -235.59%
Return on Capital Employed (ROCE) -121.74%
Revenue Per Employee $214,303
Profits Per Employee -$791,019
Employee Count 310
Asset Turnover 0.18
Inventory Turnover n/a

Taxes

In the past 12 months, Sutro Biopharma has paid $2.36 million in taxes.

Income Tax 2.36M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -73.28% in the last 52 weeks. The beta is 1.71, so Sutro Biopharma's price volatility has been higher than the market average.

Beta (5Y) 1.71
52-Week Price Change -73.28%
50-Day Moving Average 0.86
200-Day Moving Average 2.01
Relative Strength Index (RSI) 44.79
Average Volume (20 Days) 821,789

Short Selling Information

The latest short interest is 7.56 million, so 8.95% of the outstanding shares have been sold short.

Short Interest 7.56M
Short Previous Month 5.63M
Short % of Shares Out 8.95%
Short % of Float 11.49%
Short Ratio (days to cover) 8.30

Income Statement

In the last 12 months, Sutro Biopharma had revenue of $66.43 million and -$245.22 million in losses. Loss per share was -$2.98.

Revenue 66.43M
Gross Profit 54.82M
Operating Income -229.33M
Pretax Income -97.16M
Net Income -245.22M
EBITDA -221.98M
EBIT -229.33M
Loss Per Share -$2.98
Full Income Statement

Balance Sheet

The company has $248.97 million in cash and $21.40 million in debt, giving a net cash position of $227.58 million or $2.69 per share.

Cash & Cash Equivalents 248.97M
Total Debt 21.40M
Net Cash 227.58M
Net Cash Per Share $2.69
Equity (Book Value) -25.81M
Book Value Per Share -0.31
Working Capital 154.36M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$194.68 million and capital expenditures -$3.83 million, giving a free cash flow of -$198.51 million.

Operating Cash Flow -194.68M
Capital Expenditures -3.83M
Free Cash Flow -198.51M
FCF Per Share -$2.35
Full Cash Flow Statement

Margins

Gross Margin 82.52%
Operating Margin -345.20%
Pretax Margin -365.56%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Sutro Biopharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -35.16%
Shareholder Yield -35.16%
Earnings Yield -363.37%
FCF Yield -294.15%

Analyst Forecast

The average price target for Sutro Biopharma is $3.97, which is 396.87% higher than the current price. The consensus rating is "Hold".

Price Target $3.97
Price Target Difference 396.87%
Analyst Consensus Hold
Analyst Count 7
Revenue Growth Forecast (5Y) -2.43%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Sutro Biopharma has an Altman Z-Score of -4.89 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -4.89
Piotroski F-Score 1